Historical, present and potential future PCOS therapies. DPP
Download scientific diagram | Historical , present and potential future PCOS therapies . DPP-4 , dipeptidyl peptidase-4; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like ...

Conclusion The study reveals global trends in PCOS pharmacotherapy, with a growing focus on metabolic and molecular aspects. Key contributors and emerging therapies highlight the expanding scope and future potential of PCOS treatment research.
The future of PCOS management

At present , the treatments such as lifestyle correction, combined oral pills, and anti-insulin therapies along with anti-androgen drugs only have symptomatic roles with no impact on the underlying mechanism associated with PCOS .
We cannot ignore the significance and role of neuroendocrine pathophysiology in PCOS and the potential for the use of treatments which interfere with the neuroendocrine profile [11]. Promising results have emerged in the use of new drugs—NK3R antagonists, or kappa receptor agonists.

Modern Polycystic Ovary Syndrome (PCOS) Management
This review discusses these emerging approaches and their potential role in future PCOS management, aiming to transition therapy from short-term symptom control toward sustained ovarian restoration and optimized fertility outcomes.
Newer agents like metformin, GLP-1 receptor agonists, and SGLT-2 inhibitors offer targeted treatments for specific PCOS phenotypes. Precision medicine and bioinformatics have further enhanced the potential for individualized treatments, emphasizing the need for multifaceted management strategies.

A Comprehensive Review on Dipeptidyl Peptidase
DPP-4 inhibitors (pleiotropic) in addition to glycemic treatment exhibit pleiotropic characteristics (despite potential cardio- and /or normotensive effects). They have been associated with improved endothelial dysfunction, oxidative stress, and inflammation—all of which are essential in the prevention of diabetic complications.
Drawing on the latest research, this review highlights advanced glycation end products (AGEs), sex hormone-binding globulin (SHBG), and microRNAs (miRNAs) as promising targets for PCOS prevention and treatment. Future research should focus on developing targeted drugs for these molecular pathways, offering new avenues for managing PCOS .

Polycystic ovary syndrome (PCOS)
Polycystic ovary syndrome ( PCOS ) is a common gynaecological disorder, clinically characterized by chronic anovulation and hyperandrogenism. Despite its high prevalence, no curative treatment exists, and managing the syndrome remains challenging. A strong association between PCOS and metabolic syndrome, particularly insulin resistance, adversely influences fertility, leading to an increased ...







Polycystic Ovary Syndrome ( PCOS ) is characterized by a self-perpetuating vicious cycle between insulin resistance (IR) and hyperandrogenism (HA). While lifestyle management remains the internationally recommended first-line treatment, current clinical management, primarily relying on combined oral contraceptives and metformin, offers symptomatic relief or "masking" of the phenotype but ...